Industry Biotechnology Headquarters Denmark | Products Imvanex Founded 1994 | |
 | ||
Type Publicly traded Aktieselskab Traded as Nasdaq Copenhagen: BAVA Key people Paul Chaplin (President and CEO)
Gerard van Odijk (Chairman) Number of employees 409 (end 2015)
422 (end 2014) Stock price BAVA (CPH) DKK 282.00 +3.50 (+1.26%)28 Feb, 3:23 PM GMT+1 - Disclaimer Profiles | ||
Bavarian Nordic is a biotechnology company specializing in research, development and manufacture of active cancer immunotherapies and vaccines for infectious diseases. The company is headquartered in Kvistgaard, Denmark (a town in Helsingør Municipality), where it also operates a commercial-scale manufacturing facility. Research and development facilities are located in Redwood City, California, USA, and Martinsried, Germany.
Contents
- Nathaly arndtz wiedemann bavarian nordic gmbh germany vaccines 2014 omics international
- MVA BN
- Vaccinia fowlpox TRICOM
- Ebola vaccine development and production
- Pipeline
- References
The company uses viral vectors in its research and development.
Nathaly arndtz wiedemann bavarian nordic gmbh germany vaccines 2014 omics international
MVA-BN
MVA-BN is a proprietary technology developed by Bavarian Nordic. It is derived from the Modified vaccinia Ankara virus. MVA-BN is characterized by the inability to replicate in human cells, contrary to other vaccinia-based vaccines, which may replicate in humans, thus potentially causing severe and life-threatening side effects. Developed as the non-replicating smallpox vaccine, Imvamune, it is approved in Canada and in the European Union, where it is marketed as Imvanex. The vaccine is being supplied for emergency use to the U.S. Strategic National Stockpile as well as other government stockpiles. Registration studies for the approval in the U.S. are currently underway.
Vaccinia-fowlpox-TRICOM
A second poxvirus-based technology is employed in most of the company’s cancer immunotherapies, and was in-licensed as part of a collaboration with the National Cancer Institute (NCI). Vaccinia-fowlpox-TRICOM is a sequential prime-boost therapy based on vaccinia and fowlpox in combination with three co-stimulatory molecules (TRICOM). The poxvirus-based immunotherapy can be modified to encode different tumor-associated antigens such as Prostate-specific antigen (PSA), Carcinoembryonic antigen (CEA) and/or Mucin 1 (MUC1), which are all tumor markers that are overexpressed in various cancers. This technology forms the basis of the company’s lead oncology product candidates, Prostvac and CV-301. Prostvac is an active immunotherapy candidate, currently the subject of a global Phase 3 clinical study “PROSPECT” in men with asymptomatic or minimally symptomatic castration-resistant prostate cancer.
Ebola vaccine development and production
The company has worked for several years with the NIAID on the development of a filovirus vaccine for Ebola and Marburg hemorrhagic fever diseases. In October 2014, following a successful pre-clinical demonstration of the combination vaccine regimen of its multivalent MVA-BN Filovirus vaccine and Crucell/Janssen's AdVac technology based on adenoviral vectors, Bavarian Nordic joined efforts with Crucell Holland B.V., one of the Janssen Pharmaceuticals Companies of Johnson & Johnson to develop and manufacture this vaccine regimen intended for emergency use to help contain the outbreak in West Africa. In January 2015, the company had produced the first 400,000 doses of the vaccine and the first clinical trial of the vaccine regimen was initiated in the UK, with additional trials planned in the US and Africa.
Pipeline
Bavarian Nordic's pipeline, as of June 2016.
In addition, the company has multiple pre-clinical projects based on its MVA-BN technology targeting infectious diseases.
Bavarian Nordic is a member of the Alliance for Biosecurity, a group of companies that work towards preventing and treating severe infectious diseases, especially those that present global security challenges.